Live Investor Briefing Prescient Therapeutics

Prescient Therapeutics (ASX-PTX) Live Investor Briefing

Thursday 6th August 11am AEST

Please join Reach Markets Managing Director Patrick Nelson and Prescient Therapeutics CEO Steven Yatomi-Clarke for a special live investor briefing.

Event Details:

Date: Thursday 6th August 2020
Time: 11am AEST
Event Topics: 

  • Moving the cancer conversation from “fight” to “cure” showing a 100%  overall response rates as seen in a recent Johnson & Johnson trial;
  • PTX’s relationship with University of Pennsylvania, the minds behind the original CAR-T breakthrough
  • PTX’s goal of becoming the “Intel Inside” personalised cancer therapy, and more
  • How two  of PTX’s assets have been chosen as part of COVID-19 screen program

This is a live and interactive session, you simply need an internet connection to participate. Don’t miss out, spots are limited – This is a FREE event.

Book Your Spot

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.

What is a 708 investor?


Steven Yatomi-Clarke (Speak feature)

Steven Yatomi Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.